Executive severance revised at Solventum (NYSE: SOLV) with new pay and benefits

Rhea-AI Filing Summary

Solventum Corporation has updated its executive severance arrangements. On May 21, 2026, the board’s Talent Committee approved a new Solventum Executive Severance Plan, effective June 1, 2026, replacing the prior plan adopted in April 2024.

The plan covers certain employees, including executive officers, if they are involuntarily terminated without misconduct or leave for good reason, subject to a release of claims. Eligible participants may receive cash severance based on continued base salary for roughly 9 to 24 months, continued incentive eligibility, a lump‑sum for medical and dental coverage, and specified equity award treatment.

For direct reports to the Chief Executive Officer, the plan generally provides 12 months of base salary plus prorated incentive compensation after an eligible termination, while current executives who previously qualified for 18 months of salary keep that level for two years. It also clarifies forfeiture and limited vesting rules for equity awards and preserves certain grandfathered rights under earlier grants.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Severance duration range: 9 to 24 months base salary CEO direct reports severance: 12 months base salary Grandfathered higher severance: 18 months base salary +3 more

6 metrics

Severance duration range 9 to 24 months base salary Cash severance period for eligible participants

CEO direct reports severance 12 months base salary Plus prorated incentive compensation for eligible terminations

Grandfathered higher severance 18 months base salary Available to certain current executives for two years

COBRA coverage payment Lump-sum COBRA premiums Medical and dental coverage over the severance period

Plan effective date June 1, 2026 Start date of the new Executive Severance Plan

Prior plan effective date April 1, 2024 Executive Severance Plan replaced by the new plan

Key Terms

Solventum Executive Severance Plan, good reason, COBRA premiums, grandfathered rights, +1 more

5 terms

Solventum Executive Severance Plan financial

"adopted and approved the Solventum Executive Severance Plan and Summary Plan Description"

good reason financial

"in the event of an involuntary termination of employment other than for misconduct or a voluntary termination for good reason"

COBRA premiums financial

"a lump-sum cash payment equal to the amount of the COBRA premiums required for continued medical and dental coverage"

grandfathered rights financial

"the Severance Plan includes provisions intended to preserve such grandfathered rights"

Sections 280G and 409A of the Internal Revenue Code regulatory

"includes customary provisions relating to plan administration, compliance with Sections 280G and 409A of the Internal Revenue Code"

Understanding 8-K Material Events →

FALSE000196473800019647382026-05-212026-05-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 21, 2026

SOLVENTUM CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware

File No. 001-41968

92-2008841

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1750 Yankee Doodle Road, Eagan, Minnesota

55121

(Address of Principal Executive Offices)

(Zip Code)

(Registrant’s Telephone Number, Including Area Code) (651) 733-1110

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $.01 Per Share

SOLV

New York Stock Exchange

Securities registered pursuant to section 12(g) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the exchange Act.     ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 21, 2026, the Talent Committee (the “Committee”) of the Board of Directors of Solventum Corporation (the “Company”) adopted and approved the Solventum Executive Severance Plan and Summary Plan Description (the “Severance Plan”), effective June 1, 2026.

The Severance Plan provides severance payments and benefits to certain eligible employees of the Company, including executive officers, in the event of an involuntary termination of employment other than for misconduct or a voluntary termination for good reason, subject to eligibility conditions and the execution of a severance agreement, which includes a release of claims. Under the Severance Plan, eligible participants generally may receive cash severance based on a period of continued base salary (ranging from 9 months to up to 24 months), continued eligibility for incentive compensation, a lump‑sum payment for continued medical and dental coverage, and specified treatment of equity awards, in each case subject to the terms of the Severance Plan.

The Severance Plan replaces and supersedes the Company’s prior Executive Severance Plan and Summary Plan Description, effective April 1, 2024 (the “Prior Plan”).

The Severance Plan includes several changes compared to the Prior Plan, including, but not limited to:

•The Severance Plan provides for 12 months of base salary plus prorated incentive compensation following an eligible termination for direct reports of the Chief Executive Officer, provided that currently serving executive officers who are eligible to receive 18 months of base salary remain eligible for such amount for a period of two years.

•The Severance Plan provides for a lump-sum cash payment equal to the amount of the COBRA premiums required for continued medical and dental coverage for the severance period for the Chief Executive Officer and direct reports of the Chief Executive Officer and their dependents.

•The Severance Plan provides for forfeiture of certain post‑effective date awards and limited vesting for pre‑effective date awards, in each case subject to applicable plan and award terms.

Consistent with the terms of the Severance Plan, certain outstanding compensation and equity arrangements and other rights that arose under the Prior Plan or were granted prior to the effective date of the Severance Plan will continue to be governed by their existing terms (including, for example, treatment of certain equity awards granted prior to the effective date), and the Severance Plan includes provisions intended to preserve such grandfathered rights.

The Severance Plan also includes customary provisions relating to plan administration, compliance with Sections 280G and 409A of the Internal Revenue Code, and the Company’s right to amend or terminate the plan, subject to certain limitations.

The foregoing description of the Severance Plan is qualified in its entirety by reference to the Severance Plan, which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit Number						Description
10.1						Solventum Executive Severance Plan
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			SOLVENTUM CORPORATION
			By:			/s/ Wayde McMillan

Wayde McMillan

Executive Vice President and Chief Financial Officer (Principal Financial Officer)

Dated: May 27, 2026

FAQ

What executive severance changes did Solventum (SOLV) approve in May 2026?

Solventum approved a new Executive Severance Plan effective June 1, 2026. It replaces the April 2024 plan and updates severance pay, medical coverage, and equity award treatment for eligible employees, including executives, following qualifying terminations.

Who is eligible under Solventum’s new Executive Severance Plan?

The plan covers certain eligible employees of Solventum, including executive officers. Benefits apply when there is an involuntary termination not for misconduct or a voluntary termination for good reason, provided the employee meets eligibility conditions and signs a severance agreement with a release of claims.

What severance benefits do Solventum executives receive under the new plan?

Eligible participants generally may receive cash severance based on 9 to 24 months of base salary, continued eligibility for incentive compensation, a lump‑sum payment for medical and dental coverage, and specified treatment of equity awards, all subject to the detailed terms of the plan.

How are Solventum CEO direct reports treated in the updated severance plan?

Direct reports of Solventum’s CEO generally receive 12 months of base salary plus prorated incentive compensation after a qualifying termination. Currently serving executives who previously qualified for 18 months of base salary remain eligible for that higher amount for two years under grandfathering provisions.

Does Solventum’s new severance plan affect existing equity awards?

The plan provides for forfeiture of certain post‑effective date awards and limited vesting for pre‑effective date awards, subject to plan and award terms. It also preserves certain grandfathered rights so specified outstanding compensation and equity arrangements continue under their existing conditions.

How does Solventum handle medical coverage in its executive severance plan?

For the Chief Executive Officer and direct reports, the plan offers a lump‑sum cash payment equal to COBRA premiums for continued medical and dental coverage over the severance period, covering eligible dependents as well, instead of providing ongoing monthly reimbursements.

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

• EX-10.1 EX-10.1 156.8 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB